Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602207 · ClinicalTrials.gov registry record · Phase 4
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
A Phase 4 study, sponsored by Innovaderm Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT05602207: Completed Phase 4 study, sponsored by Innovaderm Research.
NCT05602207 is a Phase 4 study that has completed, run by Innovaderm Research. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05602207, a Phase 4 study, has completed, sponsored by Innovaderm Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Primary Outcome
The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of body surface area (BSA) involved for each body region and for the proportion of the body region to the whole body. The primary endpoint is the change from baseline in EASI at Week 12.
Interventions
- DRUG Abrocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 4 |
What the finished NCT05602207 record still lists
NCT05602207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Abrocitinib is the first listed.
NCT05602207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05602207 about?
NCT05602207 is a clinical study titled "Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab". This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
What is the current status of trial NCT05602207?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2022-11-25. Estimated completion is 2025-01-09.
What interventions are being tested in trial NCT05602207?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT05602207?
This trial is sponsored by Innovaderm Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05602207's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI